|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 4 (February 15), 2000:
pp. 1502-1505
BRIEF REPORT
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr
virus lymphoma after hemopoietic stem-cell transplantation
Ingrid Kuehnle,
M. Helen Huls,
Zhensheng Liu,
Micah Semmelmann,
Robert A. Krance,
Malcolm K. Brenner,
Cliona M. Rooney, and
Helen E. Heslop
From the Center for Cell and Gene Therapy and Texas Children's
Cancer Center, Baylor College of Medicine, Houston, Texas.
After bone marrow transplantation (BMT) using T-cell-depleted
marrow from an unrelated donor or HLA-mismatched related donor, the
risk of developing lymphoproliferative disease associated with the
Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that
administration of donor-derived EBV-specific cytotoxic T lymphocytes
(CTL) is effective prophylaxis and treatment for this complication, and
we routinely generate CTL for high-risk patients. However, EBV lymphoma
can occur in recipients of matched-sibling transplants for whom CTL are
unavailable or in patients for whom CTL administration is
contraindicated. We report on 3 such patients, who were successfully
and safely treated with rituximab, a CD20 monoclonal antibody. The
patients remain disease free 7, 8, and 9 months, respectively, after
therapy. We conclude that CD20 antibody may be a useful alternative
treatment strategy in patients with EBV lymphoma after BMT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Hanley, C. R. Y. Cruz, B. Savoldo, A. M. Leen, M. Stanojevic, M. Khalil, W. Decker, J. J. Molldrem, H. Liu, A. P. Gee, et al.
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
Blood,
August 27, 2009;
114(9):
1958 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Carbone, A. Gloghini, and G. Dotti
EBV-Associated Lymphoproliferative Disorders: Classification and Treatment
Oncologist,
May 1, 2008;
13(5):
577 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y.-F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al.
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Blood,
November 1, 2006;
108(9):
2942 - 2949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al.
Rituximab for steroid-refractory chronic graft-versus-host disease
Blood,
July 15, 2006;
108(2):
756 - 762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Heslop
Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas
Hematology,
January 1, 2005;
2005(1):
260 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Wagner, Y. C. Cheng, M. H. Huls, A. P. Gee, I. Kuehnle, R. A. Krance, M. K. Brenner, C. M. Rooney, and H. E. Heslop
Prompt versus preemptive intervention for EBV lymphoproliferative disease
Blood,
May 15, 2004;
103(10):
3979 - 3981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood,
February 1, 2004;
103(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications
Blood,
February 1, 2004;
103(3):
1011 - 1019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Borgmann, A. von Stackelberg, R. Hartmann, W. Ebell, T. Klingebiel, C. Peters, and G. Henze
Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis
Blood,
May 15, 2003;
101(10):
3835 - 3839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boye, T. Elter, and A. Engert
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Ann. Onc.,
April 1, 2003;
14(4):
520 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Manshouri, K.-a. Do, X. Wang, F. J. Giles, S. M. O'Brien, H. Saffer, D. Thomas, I. Jilani, H. M. Kantarjian, M. J. Keating, et al.
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
Blood,
April 1, 2003;
101(7):
2507 - 2513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop
Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children
Oncologist,
February 1, 2003;
8(1):
83 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Porcu, C. F. Eisenbeis, R. P. Pelletier, E. A. Davies, R. A. Baiocchi, S. Roychowdhury, S. Vourganti, G. J. Nuovo, W. L. Marsh, A. K. Ferketich, et al.
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration
Blood,
September 18, 2002;
100(7):
2341 - 2348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, H. G. M. Niesters, B. van der Holt, E. Meijer, A. D. M. E. Osterhaus, J. W. Gratama, L. F. Verdonck, B. Lowenberg, and J. J. Cornelissen
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
Blood,
May 29, 2002;
99(12):
4364 - 4369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Arkwright, M. Abinun, and A. J. Cant
Autoimmunity in human primary immunodeficiency diseases
Blood,
April 15, 2002;
99(8):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Carpenter, F. R. Appelbaum, L. Corey, H. J. Deeg, K. Doney, T. Gooley, J. Krueger, P. Martin, S. Pavlovic, J. Sanders, et al.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Blood,
April 15, 2002;
99(8):
2712 - 2719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Comoli, M. Labirio, S. Basso, F. Baldanti, P. Grossi, M. Furione, M. Vigano, R. Fiocchi, G. Rossi, F. Ginevri, et al.
Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication
Blood,
April 1, 2002;
99(7):
2592 - 2598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lankester, M. J. D. van Tol, J. M. Vossen, A. C. M. Kroes, and E. Claas
Epstein-Barr virus (EBV)-DNA quantification in pediatric allogeneic stem cell recipients: prediction of EBV-associated lymphoproliferative disease
Blood,
April 1, 2002;
99(7):
2630 - 2631.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Gartner, H. Schafer, K. Marggraff, G. Eisele, M. Schafer, K. Roemer, H.-J. Laws, M. Sester, U. Sester, H. Einsele, et al.
Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease
J. Clin. Microbiol.,
February 1, 2002;
40(2):
351 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Drewe and R J Powell
Clinically useful monoclonal antibodies in treatment
J. Clin. Pathol.,
February 1, 2002;
55(2):
81 - 85.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Ho and R. J. Soiffer
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood,
December 1, 2001;
98(12):
3192 - 3204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Corbellino, G. Bestetti, C. Scalamogna, S. Calattini, M. Galazzi, L. Meroni, D. Manganaro, M. Fasan, M. Moroni, M. Galli, et al.
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy
Blood,
December 1, 2001;
98(12):
3473 - 3475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, B. van der Holt, E. Meijer, H. G. M. Niesters, R. Trenschel, S. F. T. Thijsen, A. M. van Loon, F. Frassoni, A. Bacigalupo, U. W. Schaefer, et al.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
Blood,
August 15, 2001;
98(4):
972 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, S. Paczesny, V. Leblond, J.-M. Seigneurin, M. Stern, A. Achkar, M. Bauwens, V. Delwail, D. Debray, C. Duvoux, et al.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
Blood,
March 15, 2001;
97(6):
1590 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gottschalk, C. Y. C. Ng, M. Perez, C. A. Smith, C. Sample, M. K. Brenner, H. E. Heslop, and C. M. Rooney
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
Blood,
February 15, 2001;
97(4):
835 - 843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Sullivan, C. A. Dykewicz, D. L. Longworth, M. Boeckh, L. R. Baden, R. H. Rubin, and K. A. Sepkowitz
Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond
Hematology,
January 1, 2001;
2001(1):
392 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
